Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

“…It has been used for influenza virus and malaria vaccines and shown to enhance humoral and cellular protective immunity, in particular antibody response [44][45][46][47][48]. In addition, we have successfully utilized CoVaccine HT™ in our previous recombinant subunit EBOV, ZIKV and preliminary SARS-CoV-2 vaccine studies and have shown this adjuvant to elicit robust antibody responses [8][9][10]29]. Use of CoVaccine HT™ with SdTM and SdTM2P yielded significantly enhanced total IgG and neutralizing antibody responses after both the first and second dose as compared to protein alone which reached similar IgG concentrations after two doses as a single dose of the adjuvanted formulations.…”

“…The IgG antibody in mouse sera was measured by a multiplex microsphere-based immunoassay as described previously [9, 29, 30]. Briefly, internally dyed, magnetic MagPlex® microspheres (Luminex Corporation, Austin, TX) were coupled to purified receptor binding domain (RBD-F), spike protein (SdTM2P) or bovine serum albumin (BSA) as control [9, 29]. A mixture of RBD, spike SdTM2P, and BSA-coupled beads (approximately 1,250 beads each) was incubated with diluted sera in black-sided 96-well plates for 3 hours at 37°C with gentle agitation in the dark.…”

“…In previous work, we have successfully demonstrated the use of recombinant protein subunit Drosophila S2 expression system in combination with CoVaccine HT™ to produce vaccines to combat global health threats such as Zika virus (ZIKV) and Ebola virus (EBOV). Immunization with recombinant ZIKV E protein induced potent neutralizing titers in mice [9] and non-human primates [8] and protection against viremia after viral challenge. Similarly, immunization with recombinant subunit formulations consisting of the EBOV glycoprotein and matrix proteins VP40 and VP24 was able to induce potent antibody titers and protection in both mouse [10] and guinea pig models [11].…”

Ebola, the Negative Stranded RNA Virus

“…The constructed vaccine recovers the infected rhesus macaque in a single dose [62]. Similarly the glycoproteins along with the matrix proteins VP24 and VP40 and in their absence were also tested in guinea pigs [63]. The antibodies produced against these antigens completely cure the tested subjects from EBOV [63].…”

“…Similarly the glycoproteins along with the matrix proteins VP24 and VP40 and in their absence were also tested in guinea pigs [63]. The antibodies produced against these antigens completely cure the tested subjects from EBOV [63]. Several other vaccine of EBOV was developed recently and they showed promising results in murine models with high success rate [64].…”